MedTrace Logo

Systemic and Local Inflammatory Biomarkers in the Treatment of Refractory Diabetic Macular Edema

NCT06179030 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 80

Last updated 2024-01-02

No results posted yet for this study

Summary

The current study aims to investigate the relationship between systemic inflammatory biomarkers and local inflammatory biomarkers on OCT in patients with treatment resistant diabetic macular edema(DME) and further explore the associations with treatment outcomes.

Conditions

Interventions

DIAGNOSTIC_TEST

serum samples

The serum samples were taken from the patients at the 3rd month (switch point)

DRUG

dexamethasone implant versus ranibizumab

dexamethasone implant versus ranibizumab will be studied as a secondary outcome

Sponsors & Collaborators

  • Saglik Bilimleri Universitesi

    lead OTHER

Eligibility

Min Age
18 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-05-01
Primary Completion
2023-10-17
Completion
2023-10-17
FDA Drug
Yes
FDA Device
Yes

Countries

  • Turkey (Türkiye)

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06179030 on ClinicalTrials.gov